The United Kingdom and the United States have reached a key commercial pact that will guarantee zero import taxes on UK pharmaceutical products entering the US market.
Agreement Details of the Accord
In exchange for the tariff guarantee, the UK has pledged to boost expenditure on medicines through the National Health Service (NHS). This move secures that duties on these vital goods will be held at nothing for a duration of three years.
This deal follows recent statements to hike duties on patented drug imports, with figures floated as high as 100%.
"This arrangement between the United Kingdom reinforces the global environment for cutting-edge drugs and establishes much-needed balance to American-British pharmaceutical trade," an announcement declared.
Commercial Impact
Pharmaceuticals represent one of the Britain's largest export categories to the United States, which is by far the largest destination for leading companies like GSK and AstraZeneca.
Trade data indicate that in the 12 months prior to the third quarter, the UK shipped pharmaceutical products totaling over eleven billion pounds to the US. This value made up a significant portion of total UK exports in that period.
"This guarantee protects employment, increases funding and sets the stage for the UK to emerge as a international leader for life sciences," a minister stated.
Key NHS Changes
The pact includes several notable changes from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it judges new medicines to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a aim to double overall NHS spending on drugs from 0.3% of GDP to 0.6% over the next decade.
- Refund Ceiling: The amount pharmaceutical firms must pay back to the NHS to stay within budget will be capped at fifteen percent. In the past, rebates exceeded twenty percent.
Recent Tensions
The pact takes place against a long-running row between the pharmaceutical industry and the ministers over drug pricing and approval rates.
This friction were exacerbated by claims that American patients were charged a premium for the same drugs than patients in the UK and Europe.
Over the last 18 months, several significant pharmaceutical investments in the UK have been halted or abandoned, while substantial investments have been announced toward projects in the United States.
The Science Minister acknowledged that the NHS must increase expenditure on medicines, noting that its expenditure on drugs had shrunk as a share of its overall budget over the past decade.
